SCPH - חוב כולל להון scPharmaceuticals

scPharmaceuticals Inc. (SCPH) automates the synthesis of injections using algorithms, although medical supervision of patients remains with physicians. The market valuation trend for the asset's total debt-to-equity ratio is 0.00. The business relies on a proprietary furosemide delivery system that reduces clinic costs, and available funds are sufficient to promote a new cardiology drug amid a planned inventory reduction.

The commercialization of FUROSCIX requires significant expenditures, which directly impacts the balance sheet structure of scPharmaceuticals Inc. (SCPH). The current value of 0.00 reflects the proportion of borrowed funds relative to the company's equity. This metric measures the degree of financial leverage and the business's dependence on external creditors. An increase in this ratio may indicate aggressive expansion or a liquidity deficit. The historical trend of the total debt-to-equity ratio allows for an assessment of the company's resilience to its debt load.